8-K: Nexalin Tech Secures $15M+ Funding

Nexalin Technology, Inc. announced a registered direct offering and a concurrent at-the-market purchase agreement, raising substantial capital to support its operations.

Summary

• Nexalin Technology, Inc. has entered into a Securities Purchase Agreement with a single institutional investor for a registered direct offering of 2,419,355 shares of common stock at $0.31 per share, raising approximately $750,000.
• Concurrently, the company issued common stock warrants to purchase up to 1,209,677 shares of common stock at an exercise price of $0.50 per share.
• The company also entered into an Any Market Purchase Agreement (AMPA) with the same investor, allowing for the sale of up to $15 million of common stock over time, providing significant financial flexibility.
• The AMPA allows the company to sell shares at a discount to market price (92% of VWAP or 97% of the lowest traded price) under certain conditions.
• The company has agreed to file a resale registration statement for the warrant shares within 20 business days and have it declared effective within 60-75 days.
• Maxim Group LLC acted as the financial advisor for the registered direct offering, receiving a $100,000 advisory fee.
• The company has reserved sufficient authorized shares for warrant exercises and is committed to maintaining its listing on The Nasdaq Capital Market.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to the company securing significant funding through a registered direct offering and an at-the-market purchase agreement, which provides substantial financial runway and flexibility.

Positives

• Secured approximately $750,000 in gross proceeds from the registered direct offering.
• Potential to raise up to an additional $604,839 if all common warrants are exercised for cash.
• Established an at-the-market purchase agreement providing access to up to $15 million in additional capital.
• The registered direct offering and warrants are registered or have a path to registration, facilitating liquidity.
• The company has reserved sufficient shares to cover potential warrant exercises.
• Commitment to maintain listing on The Nasdaq Capital Market.

Negatives

• The registered direct offering price of $0.31 per share is significantly below recent market trading prices, indicating a need for capital.
• The exercise price of the common warrants is $0.50 per share, which may be above current market prices, potentially limiting cash exercise.
• The company is subject to potential dilution from the issuance of shares and exercise of warrants.
• The AMPA allows sales at a discount to market price, which could further depress the stock price.
• The company has agreed to pay a commitment fee of 2% ($300,000) for the AMPA, which increases to 3% if the stock is delisted within 30 days.
• Failure to file or get the resale registration statement declared effective by SEC deadlines incurs liquidated damages of $175,000.

Risks

• The company's reliance on equity financing, as evidenced by these offerings, suggests potential ongoing capital needs.
• The discount at which shares are sold under the AMPA could negatively impact shareholder value.
• The company must maintain its Nasdaq listing, and a delisting would trigger a higher commitment fee.
• The company faces potential dilution from the exercise of warrants and future sales under the AMPA.
• The company is subject to SEC registration requirements and deadlines, with penalties for non-compliance.

Future Outlook

The company has secured significant funding through a registered direct offering and an at-the-market purchase agreement, providing capital for general corporate purposes and working capital. The company is committed to maintaining its Nasdaq listing and fulfilling its registration obligations for the warrant shares.

Industry Context

StockSavvy.ai notes that this type of financing, involving registered direct offerings and at-the-market agreements, is common for companies seeking to bolster their balance sheets and fund operations, particularly in sectors requiring significant R&D or market development. The pricing and terms reflect current market conditions and the company's stage.

Stakeholder Impact

• Existing shareholders may experience dilution due to the issuance of new shares and potential exercise of warrants.
• The discounted share price in the registered direct offering and potential sales under the AMPA could negatively impact the stock price.
• The company's ability to maintain its Nasdaq listing is crucial for investor confidence and future financing.

Next Steps

• Close the registered direct offering and concurrent private placement on or about August 20, 2026.
• File a resale registration statement for the common warrant shares within 20 business days.
• Cause the resale registration statement to become effective within 60-75 days of filing.
• Maintain listing on The Nasdaq Capital Market.
• Utilize proceeds for working capital and general corporate purposes.

Key Dates

Recommendation

The company has secured necessary funding, which is a positive development. However, the terms of the financing, including discounted share prices and potential dilution, warrant a cautious approach. Investors should monitor the company's ability to execute its business plan and manage its capital effectively.

Keywords

Nexalin Technology, registered direct offering, common stock, warrants, securities purchase agreement, at-the-market purchase agreement, capital raise, Nasdaq